108 results about "Chondrocyte" patented technology

The invention relates to a diatomic iron-iron site nano-enzyme constructed by relieving oxidative stress and cartilage degeneration and used for targeted osteoarthritis treatment. According to the invention, a nitrogen-doped porous carbon anchored diatomic iron nano enzyme catalyst (Fe2-NCs) with Fe-Fe dimer coordination is developed by using a'subject-object 'strategy. The Fe2-NCs protect cartilage cells from oxidative stress induced apoptosis by modulating ROS and active nitrogen species (RNS) and promoting O2 release. In addition, Fe2-NCs restores mitochondrial function by inhibiting NOX4 expression, improving ATP production, and normalizing COXIV levels. In an in-vivo OA model, the Fe2-NCs can reduce the expression of a pro-inflammatory medium COX-2 through an NF-kappa B signal channel, inhibit the up-regulation of MMP-13 and delay the degradation of type II collagen. The invention provides a new theoretical framework and methodological approach for the treatment of osteoarthritis, and has important clinical and scientific significance.

The invention relates to a tissue engineering trachea, which combines an additive manufacturing technology with a biological material, simulates the form and the function of a natural gas pipe, designs a cartilage-fiber alternating ring structure and a bionic fiber band structure, and designs a unique blood supply channel in a fiber section. The trachea fiber section is composed of hydrogel with a hierarchical porous structure, and a circumferential blood vessel channel and a radial blood vessel pore channel are designed in the hydrogel so as to promote ingrowth and growth of new blood vessels and optimize the blood supply reconstruction process. The tracheal cartilage section is made into a C-shaped cartilage ring with cartilage cells through a biological printing technology, and necessary mechanical support is provided. The fiber segment and the cartilage segment are effectively integrated through chemical bonds of functional groups to ensure stable connection of the two. Partitioned construction of fibers and cartilage is achieved through the biological 3D printing technology, the bionic tissue engineering trachea is formed in a modular construction-integrated assembly mode, it is verified that repairing and reconstruction of multiple types of tissue bionic tracheas can be achieved, and an innovative solution is provided for tracheal injuries.

The embodiment of the invention discloses a method for constructing a cartilage micro-tissue by compounding an extracellular matrix with a vascular matrix component and application. The method comprises the following steps: preparing a porcine decellularized cartilage extracellular matrix; generating a cartilage extracellular matrix suspension; carrying out screening treatment on the cartilage extracellular matrix suspension; preparing a porcine acellular cartilage extracellular matrix microcarrier; preparing a target suspension of a common system from the porcine acellular cartilage extracellular matrix microcarrier and vascular matrix component cells, and transferring the target suspension to a bionic floating microenvironment of a shaker bioreactor for dynamic culture; carrying out culture treatment on the porcine acellular cartilage extracellular matrix microcarrier; and taking out the cell-loaded porcine decellularized cartilage extracellular matrix microcarrier from the cultured and treated porcine decellularized cartilage extracellular matrix microcarrier as the constructed cartilage micro-tissue. According to the embodiment, the condition of secondary injury to a user can be improved and reduced, the repairing effect is improved, and the adaptability of the constructed cartilage micro-tissue is improved.

The present invention relates to CD73 + CD44 + , CD90 + A method for generating a population of mesenchymal stromal cells (MSCs) is provided. + CD44 + , CD90 + MSCs are used in methods to generate terminally differentiated osteogenic, adipogenic, and chondrogenic cells from pluripotent stem cells (PSCs), which involve the use of a single agent, a WNT signaling pathway activator (e.g., a GSK3β inhibitor), in adherent cultures of PSCs.

The application discloses a functional composition for improving bone and joint health, a conditioner and application. The functional composition comprises a first active component and a second active component; the first active component comprises elastin peptide, haematococcus pluvialis and ergothioneine; and the second active component comprises one or more of houttuynia cordata and non-denatured type II collagen. The application realizes the protection effect on joint, cartilage and bone health by scientific matching of the components and synergistically improving the glycosaminoglycan level in chondrocytes and the osteocalcin level in osteoblasts. Meanwhile, the components in the functional composition for improving bone and joint health are natural and have good biocompatibility, and have no obvious side effects, so that the application provides a kind of drug or a substitute for the treatment and prevention of bone diseases.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of oleanolic acid in promoting chondrogenic differentiation of chondrocytes. This invention discovers that oleanolic acid promotes the expression of proteoglycans and calcium deposition in ATDC5 cells undergoing chondrogenic differentiation, and also promotes the expression of ATDC5 cell chondrogenic differentiation markers. Therefore, it has the potential to be formulated into a drug that can promote chondrogenic differentiation of chondrocytes, thereby promoting cartilage repair and regeneration for the treatment of osteoarthritis and rheumatoid arthritis.

The application belongs to the technical field of biomedical materials, and discloses a collagen-based double-network porous hydrogel scaffold capable of recruiting endogenous stem cells and a construction method and application thereof. The scaffold takes collagen II (Col-II) and oxidized methyl acrylated hyaluronic acid (AHAMA) as an organic phase, and is constructed into a physical / chemical double-network structure through Schiff base dynamic crosslinking and ultraviolet light-induced methacryl radical polymerization. An air-in-water emulsion template method is used to form a through-porous structure, and 5' aldehyde-modified nucleic acid aptamer Apt19S is anchored in the scaffold network to achieve specific recruitment of endogenous pluripotent stem cells. The scaffold has excellent mechanical properties, a biomimetic extracellular matrix microenvironment and a targeted stem cell recruitment function, can effectively promote the directional differentiation of stem cells into chondrocytes, avoids the immune rejection and ethical issues caused by exogenous stem cell transplantation, and is suitable for the field of articular cartilage defect repair.

The present invention relates to a method for producing cartilage tissue by selecting and choosing from chondrocytes or spheroids, and use thereof as pharmaceutical composition, medicinal product or transplant. In particular, the invention relates to markers for identifying suitable chondrocytes for producing cartilage tissue, in particular for the purpose of transplantation.

The invention relates to an ROS-responsive macrophage-chondrocyte dual-targeting nano-micelle and a preparation method and application thereof, HA capable of targeting and highly expressing CD44 cells is taken as a carrier skeleton, chemical coupling with TK and CUR is carried out in sequence, self-assembly is carried out through intermolecular force to form a stable nano-micelle, and drugs JPH203 and KGN are entrapped at the same time, so that efficient loading and targeting delivery are realized. The HA can be specifically combined with RAW264.7 macrophages and articular cartilage cells for highly expressing a CD44 receptor in an inflammatory state, and is actively delivered in a targeting manner. The ROS response characteristic of TK is utilized, oxidative fracture is carried out in an OA high ROS microenvironment, and micelles are triggered to disintegrate and release drugs accurately. The released JPH203 can inhibit an inflammatory mTOR pathway and effectively resist inflammation, and KGN is beneficial to promoting cartilage cell proliferation and effectively collecting and promoting differentiation of mesenchymal stem cells into cartilage cells, so that in-situ cartilage regeneration is realized, and a more efficient solution with low side effects is provided for osteoarthritis treatment.

The present application relates to the field of eggshell membrane peptide, in order to solve the problem that the proportion of polypeptide with main function of anti-inflammatory effect is low in the eggshell membrane peptide product obtained by hydrolysis of existing eggshell membrane, provide an eggshell membrane peptide and a preparation method thereof, and an application of the eggshell membrane peptide in preparation of anti-inflammatory drugs, comprising: S100, after adding eggshell membrane powder into pure water, adjusting pH, then adding pepsin, enzymolysis for 2-5h, and the enzymolysis temperature is 35-38 DEG C, to obtain a first mixture; S200, the first mixture is subjected to enzyme inactivation process and ultrafiltration process to obtain a first hydrolysate and a first ultrafiltrate; S300, after adjusting the pH value of the first ultrafiltrate to 8-9, adding alkaline protease, enzymolysis for 6-10h, and the enzymolysis temperature is 36-38 DEG C, to obtain a second mixture; S400, the second mixture is subjected to ultrafiltration process to obtain a second ultrafiltrate and a second hydrolysate; S500, after drying the second hydrolysate, a first polypeptide composition is obtained. The present application explores the effect of different hydrolysate components on chondrocyte anti-inflammatory, and screens out eggshell membrane peptides with better effect.

Nanoparticles suitable for delivery of a cargo to a chondrocyte, and targeting peptides comprising a chondrocyte targeting sequence, are provided. Further provided are uses of the nanoparticles and targeting peptides, for example, in treating a joint or cartilage disease or disorder.

This invention relates to the field of biomedical materials, providing non-denatured type II collagen ultrafine powder with cartilage tissue-targeted growth and structural repair functions, its bioactivity preservation preparation method, and its application in joints. The ultrafine powder has an average particle size of 0.5-50 μm, a triple helix structure integrity rate of not less than 85%, a thermal denaturation temperature of 38-48℃, and retains chondrocyte binding domains CB10, CB11, and MMP cleavage sites. The preparation method includes raw material pretreatment, time-limited enzymatic hydrolysis, graded purification, and ultra-low temperature ball milling. The product can be used for the repair and treatment of cartilage degenerative diseases such as osteoarthritis and cartilage damage.

The invention belongs to the technical field of biological medicine, and particularly relates to a small-molecule exosome-loaded composition based on bone marrow mesenchymal stem cells and application of the small-molecule exosome-loaded composition. The invention discloses the treatment effect of squalene on osteoarthritis for the first time, and further prepares the squalene-loaded bone marrow mesenchymal stem cell exosome. An in-vitro cell experiment and a model animal experiment prove that the composition has a synergistic treatment effect on osteoarthritis. In-vitro tests prove that the squalene-loaded mesenchymal stem cell exosome can improve the survival rate of inflammatory cartilage cells, inhibit release of proinflammatory factors and restore expression of repair factors. Model animal experiments prove that the squalene-loaded mesenchymal stem cell exosome has the effects of resisting inflammation, easing pain and protecting cartilage in the treatment of osteoarthritis.

The present invention discloses the use of Avn Anthramides C (Avn C) as an inducer of chondrocytic differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative cartilage therapy. By employing Avn C treatment, MSCs exhibit enhanced chondrocytic differentiation and elevated expression of key specific chondrogenic extracellular matrix (ECM) factors, notably Collagen Type II (COL2A1). Furthermore, when Avn C is used in combination with Chondroitin Sulfate (CS), a synergistic effect is observed, leading to upregulation of the transcriptional activity state of SOX9, a key regulator of chondrogenesis. The disclosed invention shows significant improvements in mRNA gene expression (ACAN, LRP1, SOX9), cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).

The present disclosure relates to mesenchymal stem cells (MSCs) for use in a method of treatment of arthritis. The MSCs are transfected with an mRNA construct encoding a pro-chondrogenic and / or chondrocyte protective factor. The pro-chondrogenic and / or chondrocyte protective factor can be WNT3a.

The invention relates to the technical field of biological medicine, and provides application of a dental pulp stem cell exosome in preparation of a medicine for treating and preventing osteoarthritis, a preparation method of the dental pulp stem cell exosome comprises the following steps: S1, obtaining dental pulp tissue from a dental pulp cavity of an in-vitro tooth; s2, pretreating dental pulp tissues, adding digestive juice, digesting, centrifuging, discarding supernatant, adding a complete culture medium containing antibiotics into precipitates, mixing, filtering and centrifuging to obtain dental pulp stem cells; and S3, culturing the dental pulp stem cells by using a complete culture medium, when the confluence degree of the dental pulp stem cells reaches 60-80%, replacing the serum-free culture medium for continuous culture, collecting the dental pulp stem cell conditioned culture medium, and performing differential centrifugation to obtain the dental pulp stem cell exosome. According to the technical scheme, the regulating effect of the dental pulp stem cell exosome on endoplasmic reticulum stress and the mechanism of the dental pulp stem cell exosome for improving cartilage cell degeneration are explored.

Provided are a chondrogenic stem cell for promoting joint repair and use thereof. Specifically, disclosed is a cell preparation used for alleviating or treating osteoarthritis, comprising a Procr-positive pluripotent stem cell. The Procr-positive chondrogenic stem cell can differentiate and generate downstream chondrocytes in vivo and promote cartilage repair in osteoarthritis damage, which will be a more effective cell treatment method. In addition, Procr proteins can be used as a new target of a drug for treating osteoarthritis.

This invention belongs to the field of biomedical technology, specifically relating to the application of bufalin in the preparation of drugs for treating osteoarthritis. The structure of bufalin is shown in the following formula. Research results of this invention show that bufalin can significantly inhibit the inflammatory response and matrix degradation of chondrocytes, protecting the extracellular matrix of chondrocytes, thereby effectively delaying or reversing the pathological progression of osteoarthritis. This invention uses the SW1353 human chondrosarcoma cell line and SD rat primary chondrocytes as in vitro experimental models. The two cell models mutually validated each other, fully demonstrating the protective effect of bufalin on chondrocytes and its potential application value in the treatment of osteoarthritis.

The invention discloses a functional composition capable of improving bone and joint health, a conditioner and application. The functional composition comprises a first active component and a second active component, the first active component is prepared from elastin peptide, haematococcus pluvialis and ergothioneine; the second active component is prepared from one or more of herba houttuyniae and non-denatured type II collagen. Through scientific compatibility of all the components, the levels of glycosaminoglycan in chondrocytes and osteocalcin in osteoblasts are synergistically improved, and the protection effect on joint, cartilage and skeleton health is achieved. Meanwhile, a plurality of components in the functional composition capable of improving the health of the bones and the joints are natural in source, good in biocompatibility and free of obvious side effects, and a medicine or an alternative scheme thereof is provided for treatment and prevention of the bone diseases.

The invention provides a synovial membrane stem cell subgroup with spontaneous chondrogenic differentiation capability and a separation method, an identification method and application thereof, the cell surface of the synovial membrane stem cell subgroup with spontaneous chondrogenic differentiation capability simultaneously expresses CDH13 and CD90, and the expression of NOTCH3 is deleted or the expression level of NOTCH3 is lower than a preset threshold value. The synovial stem cell subgroup with the spontaneous chondrogenic differentiation capacity is obtained and can be spontaneously differentiated into chondrocytes under the basic culture condition without adding growth factors, and better seed cells are provided for articular cartilage injury repair; the problems of inaccurate cartilage regeneration seed cell source, tedious induction steps and the like in the prior art are solved.

The invention discloses application of a mesenchymal stem cell combined platelet in preparation of a preparation for treating ankle arthritis, the mesenchymal stem cell combined platelet (platelet-rich plasma) is adopted to treat the ankle arthritis, the operation is simple, the side effect is small, the treatment effect is remarkable, the treatment period is short, and the application is safe and reliable. The platelet-rich plasma is rich in growth factors, can promote the regeneration of damaged tissue vessels, increase blood supply and nutrient substances, enhance the biological activity and migration ability of cartilage cells, accelerate the healing of damaged tissues around ankle joints, and effectively promote the growth and reproduction and osteogenic differentiation of bone marrow mesenchymal stem cells (BM-SCs). The method has the advantages that the cartilage differentiation of the mesenchymal stem cells at the joints is promoted, the cell repair and regeneration of the affected parts of the joints are realized, the functional recovery of the joints is promoted, and the ankle arthritis is treated more efficiently.

The invention discloses a cartilage cell targeting recombinant adeno-associated virus and a preparation method thereof, and belongs to the technical field of gene engineering. The recombinant adeno-associated virus is obtained by co-transfecting an HEK293 cell by using a recombinant plasmid pSSCMV-Cl2a1-SOX9 and a helper plasmid; and the recombinant plasmid pSSCMV-Cl2a1-SOX9 is obtained by inserting a fusion gene of Col2a1 and SOX9 into a pSSHG-CMV carrier. The preparation method comprises the following steps: step 1, constructing a recombinant plasmid pSSCMV-Col2a1-SOX9, and constructing the recombinant plasmid pSSCMV-Col2a1-SOX9; step 2, culturing the HEK293 cells, and waiting for transfection; and 3, co-transfecting the recombinant plasmid pSSCMV-Cl2a1-SOX9 obtained in the step 1, a pHelper plasmid and a pAAV-RC plasmid into the HEK293 cell cultured in the step 2, culturing, collecting a cell lysis solution, and carrying out iodixanol gradient centrifugation combined with Heparin chromatographic purification to obtain the recombinant adeno-associated virus. The recombinant adeno-associated virus obtained by the invention has targeting property and higher expression level.

The invention relates to the technical field of biological medicines, and particularly discloses application of adenosine monophosphate in preparation of a medicine for treating osteoarthritis. Cell tests show that the adenosine monophosphate solution has an inhibition effect on cartilage cell activity; animal model tests show that the adenosine monophosphate normal saline solution can remarkably relieve the cartilage injury degree of osteoarthritis mice and relieve osteoarthritis, and a new way is provided for improvement of osteoarthritis conditions. The chemical structural formula of adenosine monophosphate is shown in the specification.

The present disclosure relates to a transplantable implant comprising a biocompatible scaffold configured to be degraded over time when implanted to cartilage of a patient, the biocompatible scaffold comprising a plurality of pores, and a plurality of chondrocytes incorporated into the scaffold. In some embodiments, the implant has a longitudinal length to be implanted to an implantation hole created on the cartilage, wherein the implantation hole has an implantation depth, wherein the ratio of the full longitudinal length to the thickness of the cartilage is about 3 or less.

The present invention relates to novel long non-coding RNAs (lncRNA) involved in the regulation of hypertrophy of chondrocytes, wherein RUNX2 was regulated at the post-translational level during hypertrophic differentiation of the chondrocyte cell line TC28a2 and two novel RUNX2-binding lncRNAs among numerous lncRNAs were identified, leading to the present invention. It is expected that bone-related diseases can be diagnosed by measuring the expression of the identified specific lncRNAs, and furthermore, the vascularization or calcification of articular cartilage can be effectively suppressed by inhibiting the hypertrophy of chondrocytes through inhibiting the expression of the identified specific lncRNAs, which is expected to be highly effective in the prevention or treatment of bone-related diseases.

The present invention relates to a pharmaceutical composition for preventing or treating cartilage disease or inflammatory joint disease and a method for preparing a chondrospheroid having chondrocyte differentiation ability. The present invention provides a pharmaceutical composition comprising a stem cell-derived spheroid as an active ingredient for preventing or treating cartilage disease or inflammatory joint disease, and a method for preparing a chondrospheroid having chondrocyte differentiation ability, the method comprising the steps of: Inoculating stem cells into a three-dimensional (3D) cell culture vessel made of a plastic material; treating the stem cells inoculated into the 3D cell culture vessel with a chondrocyte differentiation-inducing factor; culturing the stem cells treated with the chondrocyte differentiation-inducing factor to form chondrospheroids; and separating the formed chondrospheroids.

The invention belongs to the field of tissue regeneration materials, and relates to a 3D printing triboelectric material and application thereof in bone and cartilage defect repair. The material can be used as 3D printing ink for manufacturing a triboelectric bracket. The scaffold is prepared by taking biodegradable PGS as a matrix, PEDOT: PSS as a conductive component and sodium chloride as a pore-forming agent through combination of 3D printing and a salt particle pore-forming method, and has a multi-stage porous structure and excellent triboelectric properties. The wire diameter, interlayer spacing and micropore distribution of the stent are accurately regulated and controlled through the 3D printing technology, so that in-situ self-energized electrical stimulation of the stent is realized in an in-vivo dynamic mechanical environment; the scaffold can promote the BMSCs to differentiate into cartilage cells, construct tissue engineering cartilage and accelerate the process of ossification in cartilage, finally realizes efficient repair of bone and cartilage defects, is excellent in biocompatibility and biodegradable, does not need an external power supply device, and has a wide clinical transformation prospect in the field of bone and cartilage defect repair.

This invention provides a hybrid exosome nanomotor driven by a pathological microenvironment, its preparation method, and its applications, belonging to the field of biomedical technology. The hybrid exosome nanomotor provided by this invention can utilize the unique oxidative microenvironment of the osteoarthritis lesion area to achieve self-driven movement, thereby actively and efficiently penetrating the dense extracellular matrix of cartilage tissue, significantly enhancing its enrichment and retention capacity in the lesion area, and promoting the specific uptake of therapeutic molecules by chondrocytes. This system not only achieves intelligent response and utilization to the disease microenvironment but also simultaneously alleviates local oxidative stress, ultimately achieving efficient, precise, and sustained therapeutic effects. This invention provides a novel, proactively targeted delivery strategy and treatment platform with promising clinical translation prospects for diseases such as osteoarthritis involving dense tissues or inflammatory microenvironments.

The invention discloses a traditional Chinese medicine concentrated solution for cell energy activation type scoliosis and a preparation process, and relates to the technical field of traditional Chinese medicine processing. The traditional Chinese medicine concentrated solution is prepared from the following raw materials in parts by weight: 100-140 parts of radix dipsaci, 80-120 parts of cortex eucommiae, 130-170 parts of radix astragali, 60-100 parts of radix angelicae sinensis, 50-70 parts of rhizoma chuanxiong, 60-80 parts of radix angelicae pubescentis, 80-100 parts of fructus lycii, 40-60 parts of radix glycyrrhizae and 15-25 parts of activation auxiliary materials. Himalayan teasel root and eucommia ulmoides in the formula are core components for strengthening muscles and bones and can enhance the toughness of ligaments and tendons around the spine; radix astragali can tonify qi, angelica sinensis can nourish blood, local blood circulation of the spine can be improved, and nutrition is provided for tissue repair; ligusticum wallichii can promote blood circulation to remove meridian obstruction, radix angelicae pubescentis can expel wind-damp, and inflammation and adhesion of soft tissues around The Chinese wolfberry fruits can nourish the liver and the kidney, the licorice roots are matched to harmonize all the medicines, the added activating auxiliary material semen cuscutae extract can activate energy metabolism of osteoblasts and chondrocytes around the spine in a targeted mode, collagen synthesis and calcium deposition are promoted, and tissue damage related to spine malformation is repaired from the cellular level.

A compound having a structure of formula (I) and a method of preparation thereof, and a use of the compound serving as an FGFR inhibitor for the treatment of tumors, cancers, myeloproliferative diseases, bone or chondrocyte disorders, and hypophosphatemia.